News & Views | Published:

Selecting antigens for cancer vaccines

Nature Biotechnology volume 30, pages 328329 (2012) | Download Citation

A cancer vaccine is streamlined by identifying a small set of potent immunogens in a tumor cDNA library.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Cancer J. 16, 304–310 (2010).

  2. 2.

    et al. Nat. Med. 17, 854–859 (2011).

  3. 3.

    et al. Nat. Biotechnol. 30, 337–343 (2012).

  4. 4.

    et al. Proc. Natl. Acad. Sci. USA 93, 14809–14814 (1996).

  5. 5.

    et al. Blood 112, 362–373 (2008).

  6. 6.

    et al. PLoS One 5, e12670 (2010).

  7. 7.

    , , & Nat. Rev. Cancer 11, 805–812 (2011).

  8. 8.

    , , & J. Clin. Invest. 116, 1935–1945 (2006).

  9. 9.

    et al. Lancet Oncol., published online, doi:10.1016/S1470–2045 (10 February 2012).

  10. 10.

    et al. N. Engl. J. Med. 364, 2119–2127 (2011).

  11. 11.

    et al. N. Engl. J. Med. 363, 711–723 (2010).

Download references

Author information

Affiliations

  1. Francesca Avogadri and Jedd D. Wolchok are at Swim Across America Laboratory, Ludwig Center for Cancer Immunotherapy and Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

    • Francesca Avogadri
    •  & Jedd D Wolchok

Authors

  1. Search for Francesca Avogadri in:

  2. Search for Jedd D Wolchok in:

Competing interests

J.D.W. is a co-inventor on patents for xenogeneic DNA immunization and an alphavirus replicon particle vaccine for TRP2.

Corresponding author

Correspondence to Jedd D Wolchok.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2174

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing